Amneal Pharmaceuticals Inc Revenue Growth Rates (AMRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amneal Pharmaceuticals Inc   (NASDAQ: AMRX)
 

AMRX's Revenue Growth by Quarter and Year

Amneal Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 796.20
1st Quarter March 722.11
FY 1,518.31

AMRXs Annual Revenue
Amneal Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 3,018.31 millions
Amneal Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 2,793.44 millions
Amneal Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 2,393.57 millions
Amneal Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 2,200.71 millions
Amneal Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 2,070.98 millions




AMRX Revenue second quarter 2026 Y/Y Growth Comment
Amneal Pharmaceuticals Inc reported Revenue growth of 9.93% year on year in the second quarter 2026, to $ 796.20 millions, this is lower than Amneal Pharmaceuticals Inc 's recent average Revenue increase of 16.07%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Revenue growth. While Amneal Pharmaceuticals Inc ' s Revenue increase of 9.93% ranks overall at the positon no. 1732 in the second quarter 2026.


AMRX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 11.59 % 18.24 % 2.3 %
3rd Quarter September - 11.75 % 13.24 % 13.84 %
2nd Quarter June 9.93 % 3.2 % 17.15 % 8.22 %
1st Quarter March 3.92 % 5.44 % 18.28 % 11.98 %
FY   - 8.07 % 16.68 % -

Financial Statements
Amneal Pharmaceuticals Inc 's second quarter 2026 Revenue $ 796.20 millions AMRX's Income Statement
Amneal Pharmaceuticals Inc 's second quarter 2025 Revenue $ 724.25 millions Quarterly AMRX's Income Statement


AMRX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 3.98 % 4.13 % -0.27 %
3rd Quarter September - 8.25 % -0.03 % 3.42 %
2nd Quarter June 10.26 % 4.23 % 6.48 % 7.51 %
1st Quarter March -11.42 % -4.88 % 6.67 % -7.74 %
FY (Year on Year)   - 8.07 % 16.68 % -


Back to AMRX Growth rate Comparisons >> Back to AMRX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #274
Overall #1732

Revenue Y/Y Growth Statistics
High Average Low
87.05 % 16.07 % -32.39 %
(Mar 31 2019)   (Dec 31 2019)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #104
Healthcare Sector #274
Overall #1732
Revenue Y/Y Growth Statistics
High Average Low
87.05 % 16.07 % -32.39 %
(Mar 31 2019)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Amneal Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
50.36 % 4.17 % -21.05 %
(Jun 30 2018)  


AMRX's II. Quarter Q/Q Revenue Comment
Amneal Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 10.26%, to $ 796.20 millions, from $722.11 millions in the first quarter.
AMRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 801.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #801
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #801
Revenue Q/Q Growth Statistics
High Average Low
50.36 % 4.17 % -21.05 %
(Jun 30 2018)  


AMRX's II. Quarter Q/Q Revenue Comment
Amneal Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 10.26%, to $ 796.20 millions, from $722.11 millions in the first quarter.
AMRX is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Amneal Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 801.


Amneal Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3,117.47 $ 3,045.53 $ 3,018.31 $ 2,933.64 $ 2,851.22
Y / Y Revenue Growth (TTM) 9.34 % 7.66 % 8.07 % 9.45 % 9.74 %
Year on Year Revenue Growth Overall Ranking # 1509 # 533 # 490 # 639 # 701
Seqeuential Revenue Change (TTM) 2.36 % 0.9 % 2.89 % 2.89 % 0.79 %
Seq. Revenue Growth (TTM) Overall Ranking # 2524 # 1672 # 1065 # 1210 # 1149


Cumulative Revenue growth Comment
Although Amneal Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 15.06% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.34% year on year, from 7.66% in Mar 31 2026.

In the Healthcare sector 254 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 533 to 1509.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 255
Overall # 1509

Revenue TTM Y/Y Growth Statistics
High Average Low
89.8 %
 15.06 %
-22.6 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2524
Cumulative Revenue growth Comment
Although Amneal Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 15.06% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 9.34% year on year, from 7.66% in Mar 31 2026.

In the Healthcare sector 254 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 533 to 1509.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 255
Overall # 1509

Revenue TTM Y/Y Growth Statistics
High Average Low
89.8 %
15.06 %
-22.6 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 370
S&P 500 # 2524




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ensign Group Inc17.33%$ 17.325 millions
Medpace Holdings Inc 17.24%$ 17.242 millions
Geron Corporation17.22%$ 17.220 millions
Si bone inc 17.16%$ 17.159 millions
Cvrx inc 16.77%$ 16.766 millions
Regeneron Pharmaceuticals Inc 16.73%$ 16.735 millions
Invo Fertility Inc 16.73%$ 16.732 millions
Pro dex Inc 16.65%$ 16.646 millions
Royalty Pharma Plc16.50%$ 16.499 millions
Acadia Pharmaceuticals Inc 16.40%$ 16.402 millions
Harvard Bioscience Inc 16.35%$ 16.352 millions
Alpha Pro Tech Ltd 15.76%$ 15.765 millions
Armata Pharmaceuticals Inc 15.72%$ 15.722 millions
Lifeward ltd 15.71%$ 15.706 millions
Novocure Limited15.60%$ 15.603 millions
Ufp Technologies Inc 15.56%$ 15.558 millions
Orthopediatrics Corp15.55%$ 15.551 millions
Jazz Pharmaceuticals Plc15.55%$ 15.548 millions
Alphatec Holdings Inc 15.35%$ 15.349 millions
Penumbra Inc14.90%$ 14.904 millions
Rockwell Medical inc 14.69%$ 14.687 millions
Sbc Medical Group Holdings Incorporated14.36%$ 14.363 millions
Nuwellis Inc 14.14%$ 14.145 millions
West Pharmaceutical Services Inc 13.89%$ 13.892 millions
Edwards Lifesciences Corporation13.66%$ 13.657 millions
Indivior Pharmaceuticals Inc 13.58%$ 13.576 millions
Talkspace Inc 13.56%$ 13.556 millions
Atricure Inc 13.38%$ 13.376 millions
Dexcom Inc 13.11%$ 13.105 millions
Sanara Medtech Inc 13.03%$ 13.028 millions


About Amneal Pharmaceuticals Inc Revenue Growth Rates (AMRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amneal Pharmaceuticals Inc (CIK 1723128).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001723128-26-000031
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amneal Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.